Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Keywords = Weissella confusa WIKIM51

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
13 pages, 243 KiB  
Article
Efficacy and Safety of WCFA19 (Weissella confusa WIKIM51) in Reducing Body Fat in Overweight and Obese Adults
by Hwayeon Sun, Jinyoung Shin, Min-ji Kim, Sunghwan Bae, Nicole Dain Lee and Byungwook Yoo
J. Clin. Med. 2024, 13(9), 2559; https://doi.org/10.3390/jcm13092559 - 26 Apr 2024
Cited by 1 | Viewed by 1433
Abstract
Background: WCFA19 (Weissella confusa WIKIM51), found during the fermentation of kimchi, is known for its inhibitory effects on body weight and body fat. This study looked at the impact of WCFA19 isolated from dandelion kimchi on weight loss in overweight and [...] Read more.
Background: WCFA19 (Weissella confusa WIKIM51), found during the fermentation of kimchi, is known for its inhibitory effects on body weight and body fat. This study looked at the impact of WCFA19 isolated from dandelion kimchi on weight loss in overweight and obese adults that are otherwise healthy. Methods: This study was conducted as a multicenter, double-blind, randomized, placebo-controlled study with 104 overweight and obese subjects. Subjects were randomized evenly into the test group (WCFA19, 500 mg, n = 40) or control group (n = 34) for 12 weeks from 14 June 2021 to 24 December 2021. Effects were based on DEXA to measure changes in body fat mass and percentage. Results: Among the 74 subjects analyzed, WCFA19 oral supplementation for 12 weeks resulted in a significant decrease in body fat mass of 633.38 ± 1396.17 g (p = 0.0066) in overweight and obese individuals in the experimental group. The control group showed an increase of 59.10 ± 1120.57 g (p = 0.7604), indicating a statistically significant difference between the two groups. There was also a statistically significant difference (p = 0.0448) in the change in body fat percentage, with a decrease of 0.41 ± 1.22% (p = 0.0424) in the experimental group and an increase of 0.17 ± 1.21% (p = 0.4078) in the control group. No significant adverse events were reported. Conclusions: Oral supplementation of 500 mg of WCFA19 for 12 weeks is associated with a decrease in body weight, particularly in body fat mass and percentage. Full article
(This article belongs to the Section Endocrinology & Metabolism)
9 pages, 1615 KiB  
Article
The Antifungal Effect of Weissella confusa WIKIM51 (Wilac D001) on Vaginal Epithelial Cells Infected by Candida albicans
by Gain Lee, Young-Ah You, Abuzar Ansari, Yoon-Young Go, Sunwha Park, Young Min Hur, Soo-Min Kim, Sang Min Park and Young Ju Kim
Appl. Sci. 2024, 14(7), 2676; https://doi.org/10.3390/app14072676 - 22 Mar 2024
Cited by 1 | Viewed by 2005
Abstract
Vulvovaginal candidiasis (VVC) is a genital infection caused by Candida albicans (C. albicans). Weissella confusa WIKIM51 (Wilac D001) is known to be detected in dandelion kimchi, produce lactic acid, and have an anti−inflammatory ability; however, its diverse antifungal effects have not [...] Read more.
Vulvovaginal candidiasis (VVC) is a genital infection caused by Candida albicans (C. albicans). Weissella confusa WIKIM51 (Wilac D001) is known to be detected in dandelion kimchi, produce lactic acid, and have an anti−inflammatory ability; however, its diverse antifungal effects have not been studied. Here, we investigated the antifungal effect of Wilac D001 in C. albicans compared to Lactobacillus species on vaginal epithelial cells (VECs). To test the antifungal ability of Wilac D001 against C. albicans on VECs, an adhesion test, pro-inflammatory cytokines (interleukin (IL)-6 and IL-8) analysis, and a disk diffusion test were performed. The acid tolerance test was conducted to investigate the viability of Wilac D001 in various acidic conditions. Lactobacillus reuteri (L. reuteri) and L. rhamnosus were used as positive controls. Wilac D001 showed the capacity to inhibit the colonization of C. albicans by adhering to VECs, with an inhibitory effect similar to that of positive controls. Both pro−inflammatory cytokines including IL−6 and IL−8 concentrations were significantly decreased when Wilac D001 was treated on C. albicans-infected VECs, respectively (p < 0.001). The result of the disk diffusion test indicates that the inhibitory ability of Wilac D001 is comparable to L. reuteri and L. rhamnosus on agar plates infected with C. albicans. Our results demonstrate that Weissella confusa WIKIM51 has antifungal effects against VECs infected by C. albicans. Full article
(This article belongs to the Special Issue Feature Review Paper in "Applied Microbiology" Section)
Show Figures

Figure 1

Back to TopTop